IMMU Immunomedics, Inc. featured news, full reports, and detailed charts
Immunomedics, Inc. (IMMU) Wrap Up:
Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We have licensed our lead product candidate, epratuzumab, to UCB, S.A., or UCB, for the treatment of all autoimmune disease indications worldwide. We have retained the rights for epratuzumab in oncology indications for which UCB has been granted a buy-in option. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f09%2f13%2f0001193125-07-200675.html#FIS_BUSINESS"Immunomedics Inc. (IMMU:NASDAQ)
Snapshot of Immunomedics Inc. (IMMU)
|
OPEN
$3.42
|
PREVIOUS CLOSE
$3.45
|
|
|
DAY HIGH
$3.62
|
DAY LOW
$3.40
|
|
|
52 WEEK HIGH
08/27/09 - $7.16
|
52 WEEK LOW
03/6/09 - $0.84
|
|
|
MARKET CAP
267.1M
|
AVERAGE VOLUME 3 mo
614.9K
|
|
|
DILUTED EPS TTM
$0.48
|
SHARES OUTSTANDING
75.2M
|
|
|
IMMU Does Not Pay Dividends
|
P/E TTM
7.4x
|
|
| K = Thousands M = Millions B = Billions | ||
IMMU Top Compensated Officers
Executives, Board Directors
Key developments for Immunomedics Inc. (IMMU)
Immunomedics Inc. reported consolidated earnings results for the first quarter ended September 30, 2009. For the quarter, the company has posted total revenues of $39.0 million and net income of $32.0 million, or $0.42 per diluted share. This compares to total revenues of $4.9 million and a net loss of $2.2 million, or $0.03 per diluted share, for the same period last year. The increase in Revenue was primarily due to the recording of license fee revenue of $31.1 million from the May 2006, development, collaboration and license agreement between the company and UCB, S.A. Operating income was $31.76 million compared to operating loss of $2.39 million for the same period a year ago. EBIT was $32.05 million compared to LBIT of $2.034 million for the same period a year ago. The net income reported this quarter is primarily from an unusual item resulting from recording the balance of the 2006 upfront licensing fee from UCB.
Immunomedics Inc. expected to Report Q2 2010 Results on February 8, 2010. This event was calculated by Capital IQ (Created on November 6, 2009).
Immunomedics Inc. - Conference Presentation Calls
IMMU Competitors
| Company | Last | Change |
| Abbott Laboratories | $53.64 USD | +0.68 |
| Amgen Inc | $55.38 USD | -0.68 |
| Biogen Idec Inc | $46.38 USD | +0.53 |
| Bristol Myers Squibb Co | $24.46 USD | +0.43 |
| Genzyme Corp | $50.05 USD | +0.42 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | IMMU | Industry Range |
| Price/Earnings | 7.4x |
|
| Price/Sales | 4.2x |
|
| Price/Book | 7.7x |
|
| Price/Cash Flow | 7.3x |
|
| TEV/Sales | 3.9x |
|
|
IMMU |
||
IMMU transactions
| Type Date |
Target |
|
Private Placement
September 3, 2009 |
-- |